Search

1. Based on the hypothesis that 25-hydroxycholecalciferol (25-OH-D3) inclusion would optimise dietary mineral digestibility and ameliorate growth performance and bone mineralisation in available phosphorus (AvP) deficient-fed broilers, a trial was conducted to evaluate its effect on diets with different levels of AvP. 2. Broilers aged 1–21 d were randomly assigned one of the eight treatments, consisting of four dietary levels of AvP (0.45%, 0.42%, 0.39%, and 0.36%) and with or without supplementation with 25-OH-D3 at 69 μg/kg of feed. All diets contained 100 µg/kg of vitamin D3 (cholecalciferol). 3. The addition of 25-OH-D3 resulted in higher feed intake and body weight gain, and lower FCR (P < 0.05) compared to non-supplemented diets, whereas AvP levels had a quadratic effect only on feed intake. There were no interactions between treatment factors. 4. Increasing AvP levels linearly reduced the ileal digestibility of Ca and P (P < 0.01) and supplementing 25-OH-D3 increased both Ca and P ileal digestibility (P < 0.05), without any interactions observed for ileal digestibility. 5. There was an interaction, whereby 25-OH-D3 inclusion increased serum metabolites in broilers fed 0.36% to 0.42% AvP compared to the non-supplemented diets (P < 0.001), whereas, at 0.45% AvP, diets with or without 25-OH-D3 had similar results. 6. The P content in bone linearly increased in line with AvP levels (P < 0.05) and supplementation of 25-OH-D3 increased ash bone content (P < 0.001). 7. Broilers can benefit from 25-OH-D3 supplementation combined with cholecalciferol with regard to Ca and P utilisation and vitamin D status, allowing for a reduction of dietary AvP levels down to 0.36% without impairing growth performance or bone status. [ABSTRACT FROM AUTHOR]

Background: The global prevalence of vitamin D (VitD) deficiency associated with numerous acute and chronic diseases has led to strategies to improve the VitD status through dietary intake of VitD-fortified foods and VitD supplementation. In this context, the circulating form of VitD3 (cholecalciferol) in the human body, 25-hydroxy-VitD3 (calcifediol, 25OHVitD3), has a much higher efficacy in improving the VitD status, which has motivated researchers to develop methods for its effective and sustainable synthesis. Conventional monooxygenase-/peroxygenase-based biocatalytic platforms for the conversion of VitD3 to value-added 25OHVitD3 are generally limited by a low selectivity and yield, costly reliance on cyclodextrins and electron donor systems, or by the use of toxic co-substrates. Results: In this study, we used a whole-cell approach for biocatalytic 25OHVitD3 synthesis, in which a molybdenum-dependent steroid C25 dehydrogenase was produced in the denitrifying bacterium Thauera aromatica under semi-aerobic conditions, where the activity of the enzyme remained stable. This enzyme uses water as a highly selective VitD3 hydroxylating agent and is independent of an electron donor system. High density suspensions of resting cells producing steroid C25 dehydrogenase catalysed the conversion of VitD3 to 25OHVitD3 using either O2 via the endogenous respiratory chain or externally added ferricyanide as low cost electron acceptor. The maximum 25OHVitD3 titer achieved was 1.85 g L–1 within 50 h with a yield of 99%, which is 2.2 times higher than the highest reported value obtained with previous biocatalytic systems. In addition, we developed a simple method for the recycling of the costly VitD3 solubiliser cyclodextrin, which could be reused for 10 reaction cycles without a significant loss of quality or quantity. Conclusions: The established steroid C25 dehydrogenase-based whole-cell system for the value-adding conversion of VitD3 to 25OHVitD3 offers a number of advantages in comparison to conventional oxygenase-/peroxygenase-based systems including its high selectivity, independence from an electron donor system, and the higher product titer and yield. Together with the established cyclodextrin recycling procedure, the established system provides an attractive platform for large-scale 25OHVitD3 synthesis. [ABSTRACT FROM AUTHOR]

Vitamin D deficiency is highly prevalent, and recent evidence suggests a possible association between vitamin D deficiency and various health conditions. The aim of this study was to assess monthly calcifediol treatments for vitamin D deficiency (or biweekly, if the deficiency was severe) in a young adult population with no associated comorbidities. This multicentre phase I trial started with a four month open-label treatment phase (TP) that included 101 participants (65% women with mean age 29.8 years). Eighty-two percent of the subjects (79/96) achieved 25(OH)D levels within the target range (20–60 ng/mL) by the end of the TP, and they were subsequently randomised and subjected to a double-blind, placebo-controlled, five month follow-up phase (FP). At the end of the FP, 89% of participants maintained vitamin D levels of >20 ng/mL with calcifediol, versus 49% with placebo (p < 0.001). Subjects receiving monthly calcifediol during both phases (n = 32) maintained 25(OH)D levels >20 ng/mL, whereas those on the placebo during the FP (n = 38) exhibited deficiency levels of 25(OH)D by the end of the study. No clinically relevant changes in bone metabolism parameters or toxic 25(OH)D levels were observed, and no serious adverse events were reported throughout the study. Calcifediol is a safe and effective treatment for vitamin D deficiency in the young adult population, but long-term use may be required to sustain optimal 25(OH)D levels. [ABSTRACT FROM AUTHOR]

EFSA was asked by the European Commission to provide scientific assistance with respect to the EFSA adopted scientific opinion on 'Safety of calcidiol monohydrate produced by chemical synthesis as a novel food pursuant to Regulation (EU) 2015/2283', including its bioavailability as a metabolite of vitamin D3 when added for nutritional purposes to food supplements. On 5 July 2023, EFSA adopted the 'Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate'. This opinion concerns an updated exposure assessment for vitamin D and proposes a conversion factor for calcidiol monohydrate into vitamin D3 of 2.5 for labelling purposes. In addition, in reference to the EFSA opinion on the safety of calcidiol monohydrate, the Commission had received a letter from the pharmaceutical company EirGen Pharma Ltd requesting a revision of this opinion based on new data concerning calcidiol. Based on the information and data considered in this scientific technical report, EFSA concludes that the novel food calcidiol monohydrate proposed for use in food supplements is a bioavailable source of the biologically active metabolite of vitamin D, i.e. 1,25‐dihydroxyvitamin D, that a conversion factor of 2.5 reflects the relative bioavailability of calcidiol vs vitamin D3 under the proposed conditions of use and use levels, and that it is safe under the proposed conditions of use and use levels, i.e. up to 10 μg/day for children ≥ 11 years old and adults, including pregnant and lactating women, and up to 5 μg/day for children 3–10 years of age. [ABSTRACT FROM AUTHOR]

Background: An ongoing debate has been raised on whether is better to use total or free calcidiol as a screening test in the population. Methods: In winter and summer, free calcidiol, total calcitriol, and vitamin D binding protein (DBP) concentrations were determined by immunoenzymatic assays in 326 adults (161 males, 165 females). These included 99 osteoporotic patients, 53 type 1 and 51 type 2 diabetics, and 123 athletic healthy persons, all from northern Greece. Results: In the whole sample, free calcidiol mean concentrations differed significantly (p < 0.001) between males (5.53 pg/ml) and females (4.68 pg/ml). Free calcidiol was significantly greater in the athletic healthy group (6.02 pg/ml) than in the three patient groups, and lowest in the osteoporosis group (3.69 pg/ml). Total calcitriol mean concentration did not differ significantly between genders in the whole sample (p = 0.896) or in the study groups, except for type 2 diabetics (males 38.33 pg/ml, females 54.52 pg/ml, p = 0.001). It was significantly less in the osteoporotics (34.61 pg/ml) than in the athletic healthy group (41.65 pg/ml, p = 0.037) and type 1 diabetics (43.73 pg/ml, p = 0.030), whereas it did not differ significantly between the other study groups. The DBP mean concentrations were not significantly different between genders in the whole sample and the study groups nor among the study groups (p = 0.467). Conclusions: Comparisons with our previously reported results of total calcidiol suggest the measurement of free calcidiol offers nothing more than that, and total calcitriol is not a sensitive measure for assessing vitamin D status. [ABSTRACT FROM AUTHOR]

This study aimed to investigate the effects of different concentrations of in ovo injection of 25-hydroxycholecalciferol (25(OH)D3) on early growth, immune and tibia development in Daheng broilers. The results showed that 25(OH)D3 can significantly improve the hatchability of broilers and improve body weight (p < 0.05). The low concentration of 25(OH)D3 (8 μg/mL) not only significantly increased tibial fresh weight, tibial length, tibial diameter, thymus and liver weight and immune organ index (p < 0.05), but also significantly increased the content of bone metabolism-related factors OC and CaBP in serum and the expression levels of OC in the liver (p < 0.05). However, a high concentration of 25 (OH)D3 group (16 μg/mL) significantly increased bursa of Fabricius weight and immune organ index (p < 0.05), the content of immune factor IL-2, IFN-γ and TLR15 in serum and the expression level of IFN-γ and TLR15 in the spleen (p < 0.05). Furthermore, the content of ash, calcium and phosphorus in the tibia was negatively correlated with the expression level of OC and positively correlated with the expression level of ALP (p > 0.05). Our data suggested that 25(OH)D3 has positive effects on the early growth, immune, bone development of broiler during the early stage, which is a supplement to improve disease resistance and skeletal development of broilers. [ABSTRACT FROM AUTHOR]

In ovo injection of the Marek's disease (MD) vaccine (MDV) has been widely practiced in commercial US hatcheries. However, the MDV is very sensitive and may not be compatible with some nutrients when administered together by in ovo injection. When individually administered by in ovo injection, L-Ascorbic acid (L-AA) and 25-hydroxyvitamin D3 (25OHD3) have previously exhibited very promising results on the post-hatch physiological and immunological characteristics of broilers subjected to stressful commercial conditions. However, the compatibility of the MDV with these vitamins has not been previously explored. Their compatibility must first be established before their combined administration by in ovo injection can be considered. Therefore, the objective in this study was to determine the compatibility of the MDV with various levels of 25OHD3 or L-AA. The treatments employed were MDV-alone, MDV in combination with 0.6 (low) or 2.4 (high) μg doses of 25OHD3, or MDV in combination with 1.2 (low) or 12 (high) mg doses of L-AA. The live and dead ratio of primary chick embryo fibroblast cells infected by the MD virus (CEF-MDV) in each treatment was determined every 30 min for 2 h. The L-AA at both the low and high doses resulted in a 70% death of CEF-MDV within 1 h, but either dose of the 25OHD3 exhibited only an approximate 5% lower CEF-MDV survival as compared to those in the MDV-alone treatment. Therefore, it is suggested that the two designated doses of 25OHD3 have the potential to be effectively combined with the MDV for subsequent administration by in ovo injection. [ABSTRACT FROM AUTHOR]

This study aimed to investigate the effects of different concentrations of in ovo injection of 25-hydroxycholecalciferol (25(OH)D3) on early growth, immune and tibia development in Daheng broilers. The results showed that 25(OH)D3 can significantly improve the hatchability of broilers and improve body weight (p < 0.05). The low concentration of 25(OH)D3 (8 μg/mL) not only significantly increased tibial fresh weight, tibial length, tibial diameter, thymus and liver weight and immune organ index (p < 0.05), but also significantly increased the content of bone metabolism-related factors OC and CaBP in serum and the expression levels of OC in the liver (p < 0.05). However, a high concentration of 25 (OH)D3 group (16 μg/mL) significantly increased bursa of Fabricius weight and immune organ index (p < 0.05), the content of immune factor IL-2, IFN-γ and TLR15 in serum and the expression level of IFN-γ and TLR15 in the spleen (p < 0.05). Furthermore, the content of ash, calcium and phosphorus in the tibia was negatively correlated with the expression level of OC and positively correlated with the expression level of ALP (p > 0.05). Our data suggested that 25(OH)D3 has positive effects on the early growth, immune, bone development of broiler during the early stage, which is a supplement to improve disease resistance and skeletal development of broilers. [ABSTRACT FROM AUTHOR]

Background: Vitamin D has multiple extra-skeletal functions. Among them are some important roles in reproductive system and many aspects are still under evaluation. It is not surprising because vitamin D seems to be involved in almost every physiological process that takes place in the reproductive system. Active form of vitamin D –calcitriol – 1,25OH2D3 plays a significant role in anti-proliferative and immu)nosuppressive processes in the body. Evaluation of endometriosis in some studies showed changed vitamin D metabolism in tissue and ad)vanced parallel activation and degradation of calcitriol in cells of endometriosis. Aim: We aimed to observe literature to review current knowledge about the connection of endometriosis and vitamin D – calcidiol and calcitriol. Our main interest is to summarize latest studies, based on them make some conclusions and suggest directions for future studies. Key interest is to find out how affects vitamin D endometriosis and vice versa in both clinical and experimental studies. Materials and Methods: Electronic databases such: PubMed, Medline, Cochrane Library, Web of Science, Science Direct, Springer were searched. 75 articles were reviewed. 29 articles that had statistically significant results were included in our review. Results: Clinical studies from the last few years are more about the associative connection of low 25OHD3 and endometriosis. Researchers are concentrated more on calcidiol-25OHD3 and do not pay much attention to calcitriol-1,25OHD3. Mainly they see low calcidiol as a risk factor for endometriosis and few think that low 25OHD3 may be the consequence of active conversion of 25OHD3 to 1,25OHD3. Asso)ciation between low calcidiol -25OHD3 and endometriosis is studied the most. Most of the studies have found that patients with endome)triosis have lower levels of 25OHD3. Only two studies measured both calcitriol and calcidiol in blood of women with endometriosis and result are controversial. Evidence is low and insufficient to discuss about the reasons and consequences of changed metabolism. Conclusions: According to reviewed research we do not have enough data to insist that vitamin D metabolism is different in endometriosis. But it seems to be so. It is important to understand which is risk factor for another- low 25OHD3 raises risk of endometriosis or vice versa? If high activation of 25OHD3 to 1,25OHD3 and following high degradation of 1,25OHD3 occurs during endometriosis in endometrial tissue, what is the consequence of it in blood and are these consequences important enough to notice? May it affect calcium homeostasis? It should be mentioned that experimental treatment of endometriosis with calcitriol analogs shows promising effects. If management of endometriosis with help of calcitriol analogs will be available in the future, it will be important to have some basic knowledge about primary calcitriol and calcidiol levels in blood during endometriosis. Outcome of this different vitamin D metabolism in endometrial tissue may be high, low or normal calcit)riol levels in blood. But substrate for conversion – 25OHD3 calcidiol should be theoretically low, because of high demand. Persistent hypercal)citriolemia may lead to hypercalcemia and cause harm to multiple organ systems. Thus, normalization of vitamin D metabolites should receive proper attention and be corrected as well. [ABSTRACT FROM AUTHOR]

Introduction: Seborrheic keratoses (SK) are benign epidermal tumors with high sun exposure as a major risk factor. Vitamin D deficiency is also thought to play a role in its pathogenesis. There has been no data regarding SK, calcidiol level, vitamin D intake, and sun index (SI) among people living in coastal areas in Indonesia. Objective: To assess the correlation between 1) serum calcidiol levels with SI and vitamin D intake and 2) lesion size with SI and serum calcidiol level among SK patients living in a coastal area. Methods: This is a cross-sectional study. We performed interviews using the sun index questionnaire and semiquantitative food frequency questionnaire for vitamin D; physical examination; dermoscopy to determine the largest SK lesion size; and measurement of serum calcidiol levels in participants with SK living in Cilincing District, North Jakarta. Spearman correlation test was used to assess the relationship between variables. Results: Thirty-nine participants with SK aged 19–59 years old were analyzed. The median of the SK’s largest diameter, sun index, serum calcidiol, and vitamin D intake was 2 (1–10) mm, 3.95 (1.1–23.52), 14.3 (5.25–35.30) ng/ml, and 4.3 (0.1–30.1) mcg/day, respectively. Sun index and vitamin D intake were not significantly correlated with calcidiol levels. Similarly, SI and calcidiol levels were not significantly correlated with the largest SK lesion size. Conclusion: We found low calcidiol levels and vitamin D intake in this coastal population. The SI and vitamin D intake had no correlations with calcidiol levels. Furthermore, calcidiol levels and SI had no correlations with the lesion’s largest diameter.

BackgroundDifferent 25-hydroxyvitamin D [25(OH)D] thresholds for treatment with vitamin D supplementation have been suggested and are derived almost exclusively from observational studies. Whether other characteristics, including race/ethnicity, BMI, and estimated glomerular filtration rate (eGFR), should also influence the threshold for treatment is unknown.ObjectivesThe aim was to identify clinical and biomarker characteristics that modify the response to vitamin D supplementation.MethodsA total of 666 older adults in the Multi-Ethnic Study of Atherosclerosis (MESA) were randomly assigned to 16 wk of oral vitamin D3 (2000 IU/d; n = 499) or placebo (n = 167). Primary outcomes were changes in serum parathyroid hormone (PTH) and 1,25-dihydroxyvitamin D [1,25(OH)2D] concentrations from baseline to 16 wk.ResultsAmong 666 participants randomly assigned (mean age: 72 y; 53% female; 66% racial/ethnic minority), 611 (92%) completed the study. The mean (SD) change in PTH was -3 (16) pg/mL with vitamin D3 compared with 2 (18) pg/mL with placebo (estimated mean difference: -5; 95% CI: -8, -2 pg/mL). Within the vitamin D3 group, lower baseline 25-hydroxyvitamin D [25(OH)D] was associated with a larger decline in PTH in a nonlinear fashion. With baseline 25(OH)D ≥30 ng/mL as the reference, 25(OH)D

As well as being essential for musculoskeletal health, vitamin D is involved in numerous other physiological processes. Poor vitamin D status is linked to a wide range of diseases, including cardiovascular disease, autoimmune conditions, pulmonary disorders and upper respiratory tract infections. While optimal target concentrations of serum 25-hydroxyvitamin D (25(OH)D) for health maintenance or therapeutic purposes are still the subject of debate, there is reasonable agreement that serum 25(OH)D levels

Abstract Background Previous studies have documented vitamin D imbalance in dogs with acute pancreatitis (AP), but no studies have investigated serum vitamin D receptor (VDR) and vitamin D‐binding protein (VDBP) concentrations. Objectives Compare serum 25‐hydroxyvitamin D (25[OH]D), VDR, and VDBP concentrations in healthy dogs and dogs with AP and identify correlations between these concentrations with ionized calcium, C‐reactive protein (CRP), and canine‐specific pancreatic lipase (Spec cPL) concentrations. Animals Twenty‐two dogs with AP and 20 healthy control dogs. Methods Prospective cross‐sectional study. Serum 25(OH)D concentrations were measured using a chemiluminescence immunoassay, and VDR and VDBP concentrations were measured using a ELISA kit designed for dogs. Results Serum concentrations of 25(OH)D were lower in dogs with AP (mean ± SD, 66.1 ± 39.2 ng/mL) than in controls (96.8 ± 30.4 ng/mL; P = .01), and VDR concentrations were lower in dogs with AP (5.3 ± 3.5 ng/mL) than in controls (7.4 ± 2.5 ng/mL; P = .03). No difference was observed in serum VDBP concentrations between the groups. Serum VDR concentrations differed between survivors (median [interquartile range] = 6.6 [4.3‐8.2] ng/mL) and nonsurvivors (2.7 [0.5‐3.5] ng/mL; P = .01). Negative correlations were observed among serum VDR, CRP (rs = −0.55), and Spec cPL (rs = −0.47) concentrations in dogs with AP. Conclusions and Clinical Importance Dogs with AP had lower serum 25(OH)D and VDR concentrations than controls. Additionally, our study suggests a potential role of VDR expression in the inflammatory process of AP in dogs.

Recent studies have suggested that 25-hydroxyvitamin D (25(OH)D) may be a poor biomarker of bone health, in part because measured levels incorporate both protein-bound and free vitamin D. The ratio of its catabolic product (24,25-dihydroxyvitamin D [24,25(OH)2 D]) to 25(OH)D (the vitamin D metabolite ratio [VMR]) may provide more information on sufficient vitamin D stores and is not influenced by vitamin D-binding protein concentrations. We evaluated whether the VMR or 25(OH)D are more strongly associated with bone loss and fracture risk in older adults. We performed a retrospective cohort study of 786 community-dwelling adults aged 70 to 79 years who participated in the Health Aging and Body Composition study. Our primary outcomes were annual changes in bone density and incident fracture. The mean age of these participants was 75 ± 3 years, 49% were female, 42% were Black, and 23% had an estimated glomerular filtration rate (eGFR)